Global Immuno-oncology Therapy Market Growth (Status and Outlook) 2023-2029
Cancer immunotherapy (sometimes called immuno-oncology) is the use of the immune system to treat cancer.
LPI (LP Information)' newest research report, the “Immuno-oncology Therapy Industry Forecast” looks at past sales and reviews total world Immuno-oncology Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Immuno-oncology Therapy sales for 2023 through 2029. With Immuno-oncology Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immuno-oncology Therapy industry.
This Insight Report provides a comprehensive analysis of the global Immuno-oncology Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immuno-oncology Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immuno-oncology Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immuno-oncology Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immuno-oncology Therapy.
The global Immuno-oncology Therapy market size is projected to grow from US$ 1206.2 million in 2022 to US$ 1660 million in 2029; it is expected to grow at a CAGR of 4.7% from 2023 to 2029.
United States market for Immuno-oncology Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Immuno-oncology Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Immuno-oncology Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Immuno-oncology Therapy players cover Amgen, AstraZeneca, Bristol-Myers Squibb, Eli-Lilly, Roche, GlaxoSmithKline, Janssen Biotech, Merck and Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Immuno-oncology Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Segmentation by application
Hospitals
Ambulatory Surgical Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
AstraZeneca
Bristol-Myers Squibb
Eli-Lilly
Roche
GlaxoSmithKline
Janssen Biotech
Merck
Novartis
Pfizer
Sanofi
Spectrum Pharmaceuticals
Takeda
BioNTech SE
Allogene Therapeutics
IMAB-I-Mab Biopharma Co., Ltd.
Arcus Biosciences
Gritstone Oncology
Autolus Therapeutics
Rubius Therapeutics
Please note: The report will take approximately 2 business days to prepare and deliver.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook